Understanding GLP-1 Drugs
Evidence-based guides on semaglutide, tirzepatide, and other GLP-1 receptor agonists for weight loss and diabetes management.
116 Articles
HRS-7535 (KAI-7535): The Oral GLP-1 Pill With 11% Weight Loss
HRS-7535, or KAI-7535, is Hengrui and Kailera's oral small-molecule GLP-1 pill. Phase 3 data in China showed up to 11.1% weight loss. Here's the science.
Metabolic Science Editorial
GLP-1 Medications and Fatigue: Why You Feel Tired and What Helps
Why GLP-1 medications like Ozempic and Zepbound cause fatigue, what trial data shows about how common it is, when tiredness peaks, and evidence-based ways to manage it.
Metabolic Science Editorial
UBT251: Novo Nordisk's Triple Agonist With 19.7% Weight Loss
Novo paid $200M upfront for UBT251, a GLP-1/GIP/glucagon triple agonist that produced 19.7% weight loss at 24 weeks in China. What the data show.
Metabolic Science Editorial
MET-097i (PF'3944): Pfizer's Monthly GLP-1 Shot Explained
MET-097i is Pfizer's once-monthly GLP-1. Phase 2b showed 14.1% weekly and 12.3% monthly placebo-adjusted weight loss with unusually low dropout rates.
Metabolic Science Editorial
CX11 (VCT220): The Oral GLP-1 Pill With 12% Weight Loss
CX11, also called VCT220, is an oral small-molecule GLP-1 pill from Corxel and Vincentage. Phase 3 data in China showed 12.4% weight loss. Here's the science.
Metabolic Science Editorial
GLP-1 Medications and Taste Changes: Why Food Tastes Different
Roughly 1 in 5 people on semaglutide or tirzepatide say food tastes different. Here's what the research shows about GLP-1 taste changes — and what helps.
Metabolic Science Editorial
Ribupatide (HRS9531): The GLP-1/GIP Rival From China
Ribupatide delivered 19.2% weight loss in a Chinese Phase 3 trial and is now in global Phase 3 against semaglutide. What the data show — and what they don't.
Metabolic Science Editorial
GLP-1 Medications and Intermittent Fasting: Can You Combine Them?
Can you safely combine GLP-1 medications and intermittent fasting? What the research shows on weight loss, muscle preservation, hypoglycemia risk, and how to eat.
Metabolic Science Editorial
Aleniglipron: The Oral GLP-1 Pill With 16% Weight Loss
Aleniglipron is Structure Therapeutics' once-daily oral small-molecule GLP-1 pill. Phase 2 trials show up to 16% weight loss. Here's what the science says.
Metabolic Science Editorial
GLP-1 Medications and Birth Control: What the Research Shows
Do GLP-1 medications weaken birth control? Tirzepatide can cut pill absorption by ~20%, while semaglutide does not. Here's what the science says and how to stay protected.
Metabolic Science Editorial
GLP-1 Medications and Inflammatory Bowel Disease: The Evidence
Can GLP-1 drugs help Crohn's and ulcerative colitis? New 2025 meta-analyses link them to fewer surgeries and hospitalizations in IBD. Here's the data and the caveats.
Metabolic Science Editorial
GLP-1 Medications and Your Menstrual Cycle: The Research
GLP-1 medications like Ozempic and Wegovy can change your period—restoring ovulation, shifting cycle length, and affecting birth control. Here's what the science shows.
Metabolic Science Editorial
GLP-1 Medications and Hidradenitis Suppurativa: The Evidence
GLP-1 drugs are showing up in hidradenitis suppurativa research with lower flare rates and fewer biologic escalations. Here's what the 2026 systematic reviews actually found.
Metabolic Science Editorial
Eloralintide: Lilly's Amylin Drug With 20% Weight Loss
Eloralintide is Eli Lilly's selective amylin receptor agonist that produced 20% weight loss in a 48-week Phase 2 trial. Here's what the Lancet data actually show.
Metabolic Science Editorial
CT-388: Roche's Dual GLP-1/GIP Agonist With 22.5% Weight Loss
Roche's CT-388 delivered 22.5% placebo-adjusted weight loss in Phase 2 and resolved obesity in 54% of patients at the top dose. The signaling-biased science explained.
Metabolic Science Editorial
GLP-1 Medications and Psoriasis: What the Research Shows
The National Psoriasis Foundation now backs GLP-1 drugs as an add-on for psoriasis with metabolic disease. Here's the trial evidence, the PASI numbers, and who benefits.
Metabolic Science Editorial
GLP-1 Medications in Older Adults: Sarcopenia and Frailty Risk
GLP-1 drugs like semaglutide work well after 65, but muscle loss, frailty, and weight regain carry higher stakes with age. Here's what the evidence shows.
Metabolic Science Editorial
GLP-1 Medications and Infection Risk: What the Research Shows
Do GLP-1 drugs like semaglutide raise or lower infection risk? Large meta-analyses now point to fewer serious infections, pneumonia, and COVID-19 deaths. Here's the evidence.
Metabolic Science Editorial
GLP-1 Medications and Dizziness: What the Research Shows
Why GLP-1 medications like Ozempic and Zepbound can cause dizziness, the difference between lightheadedness and true vertigo, and evidence-based ways to manage it.
Metabolic Science Editorial
Efpeglenatide: The Weekly GLP-1 With Cardio-Renal Benefits
Efpeglenatide is an exendin-based weekly GLP-1 that cut heart and kidney events in the AMPLITUDE-O trial and drove up to 7.2 kg of weight loss. Here's the full evidence.
Metabolic Science Editorial
GLP-1 Medications and Dehydration: Risks and Prevention
Why GLP-1 medications like Ozempic and Zepbound raise dehydration risk, the link to acute kidney injury, and evidence-based steps to stay hydrated safely.
Metabolic Science Editorial
GLP-1 Medications and Testosterone: What the Research Shows
Can Ozempic, Wegovy, and Mounjaro raise low testosterone in men? Here's what trials and meta-analyses show about GLP-1 drugs, weight loss, and male hormones.
Metabolic Science Editorial
GLP-1 Medications and Acid Reflux: What the Research Shows
Do Ozempic, Wegovy, and Mounjaro cause acid reflux? Here's what cohort studies and meta-analyses show about GERD risk, why delayed stomach emptying drives it, and how to manage it.
Metabolic Science Editorial
GLP-1 Medications and Heart Rate: Why They Speed It Up
Do Ozempic, Wegovy, and Mounjaro raise your heart rate? Here's what meta-analyses show about the 2–7 bpm increase, why it happens at the sinus node, and whether it's dangerous.
Metabolic Science Editorial
GLP-1 Drugs and COPD: Can Mounjaro or Ozempic Help?
Read the COPD evidence for GLP-1 drugs, including a small liraglutide trial and tirzepatide cohort data, plus what these studies cannot establish.
Metabolic Science Editorial
GLP-1 Medications and Hypoglycemia: Real Risk and How to Manage It
Do GLP-1 drugs cause low blood sugar? On their own the risk is under 1%, but it climbs sharply with insulin or sulfonylureas. Here's what the evidence shows.
Metabolic Science Editorial
GLP-1 Medications for Prediabetes: Can They Prevent Type 2 Diabetes?
GLP-1 medications for prediabetes reversed high blood sugar in 81–84% of patients and cut type 2 diabetes risk by 94% in trials. Here's what the evidence shows.
Metabolic Science Editorial
Wegovy HD (Semaglutide 7.2 mg): What the STEP UP Trial Shows
Wegovy HD delivers semaglutide 7.2 mg — the FDA's newest high-dose obesity drug. STEP UP showed up to 20.7% weight loss. Here's the evidence, dosing, and safety.
Metabolic Science Editorial
GLP-1 Medications and Diarrhea: Why It Happens and How to Manage It
Diarrhea hits roughly 1 in 3 people on semaglutide and 1 in 5 on tirzepatide. Here's the surprising reason a drug that slows the gut still loosens stools — and how to manage it.
Metabolic Science Editorial
GLP-1 Medications and Constipation: Why It Happens and How to Manage It
Constipation affects roughly 1 in 4 people on semaglutide and tirzepatide. Here's why GLP-1 medications slow the gut — and the evidence-based ways to keep things moving.
Metabolic Science Editorial
GLP-1 Medications and Nausea: Why It Happens and How to Manage It
Nausea is the most common GLP-1 side effect, affecting up to 44% of users. Here's why semaglutide and tirzepatide cause it — and how to manage it without quitting.
Metabolic Science Editorial
GLP-1 Medications and Stroke: What the Research Shows
Do GLP-1 drugs like Ozempic and Trulicity lower stroke risk? Trials of 60,000+ patients show a 15-17% reduction in nonfatal and ischemic stroke.
Metabolic Science Editorial
GLP-1 Medications and Atrial Fibrillation: What the Research Shows
Do GLP-1 drugs like Ozempic raise or lower atrial fibrillation risk? Pooled trials of 40,000+ patients show an 18% lower AFib risk, beyond weight loss alone.
Metabolic Science Editorial
GLP-1 Medications and Smoking Cessation: What the Research Shows
Can Ozempic and Wegovy help you quit smoking? Here's what a 222,942-patient analysis and a randomized trial reveal about GLP-1 drugs, nicotine cravings, and post-quit weight gain.
Metabolic Science Editorial
Ecnoglutide: The cAMP-Biased GLP-1 Driving 13% Weight Loss
Ecnoglutide is a once-weekly biased GLP-1 receptor agonist from Sciwind that delivered 13.2% weight loss in Phase 3. Here's how the SLIMMER and EECOH-1 data stack up.
Metabolic Science Editorial
Ozempic Face: Causes, Prevention, and What the Research Shows
Ozempic face — facial volume loss from rapid GLP-1 weight loss — is real and measurable. Here's the science behind why it happens and how to prevent it.
Metabolic Science Editorial
Petrelintide: Roche's Amylin Analog for Weight Loss
Petrelintide is a long-acting amylin analog from Zealand and Roche delivering double-digit weight loss with mild GI side effects. Here's what the Phase 2 data show.
Metabolic Science Editorial
GLP-1 Medications and Gout: What the Research Shows
Does Ozempic raise or lower gout risk? The research shows a transient uric-acid spike during rapid weight loss — and why SGLT2 drugs beat GLP-1s for gout.
Metabolic Science Editorial
GLP-1 Medications and Asthma: What the Research Shows
Can GLP-1 drugs like Ozempic and Wegovy reduce asthma attacks? Here's what cohort studies in adults and teens reveal about exacerbations, steroids, and airway inflammation.
Metabolic Science Editorial
Bimagrumab and Semaglutide: Fat Loss That Spares Muscle
Bimagrumab blocks activin receptors to build muscle. In the phase 2 BELIEVE trial, adding it to semaglutide preserved lean mass while 93% of weight lost was fat.
Metabolic Science Editorial
Pemvidutide: The GLP-1/Glucagon Dual Agonist With 15.6% Weight Loss
Altimmune's pemvidutide hit 15.6% weight loss in Phase 2 MOMENTUM with class-leading lean mass preservation, and won FDA Breakthrough status in MASH. The full evidence.
Metabolic Science Editorial
GLP-1 Medications and Peripheral Artery Disease: What the Research Shows
The STRIDE trial showed semaglutide improves walking distance in peripheral artery disease. Here's what GLP-1 medications mean for limb and heart outcomes in PAD.
Metabolic Science Editorial
GLP-1 Medications and Metabolic Syndrome: What the Research Shows
Can GLP-1 drugs like Ozempic and Mounjaro reverse metabolic syndrome? Here's what randomized trials show about each of its five cardiometabolic risk factors.
Metabolic Science Editorial
VK2735: Viking Therapeutics' Dual GIP/GLP-1 Obesity Drug
VK2735 produced up to 14.7% weight loss in just 13 weeks, as both a weekly shot and a daily pill. How Viking Therapeutics' dual GIP/GLP-1 drug works.
Metabolic Science Editorial
Amycretin: Novo Nordisk's GLP-1 + Amylin Drug With 22% Weight Loss
Amycretin delivers up to 22% weight loss in early trials and comes as both a weekly shot and a daily pill. How Novo Nordisk's GLP-1 + amylin agonist works.
Metabolic Science Editorial
GLP-1 Medications and Longevity: Can They Slow Aging?
Can GLP-1 drugs like Ozempic and Mounjaro slow biological aging and help you live longer? Here's what randomized trials and aging research actually show.
Metabolic Science Editorial
GLP-1 Medications for Binge Eating Disorder: What the Research Shows
Can semaglutide, liraglutide, or dulaglutide reduce binge eating episodes? A review of pilot trials, mechanisms, and what current evidence means for BED treatment.
Metabolic Science Editorial
Tirzepatide vs Retatrutide: Trial Results and Key Differences
Compare tirzepatide and investigational retatrutide: trial populations, weight-loss results, TRIUMPH studies and why separate trials cannot prove superiority.
Metabolic Science Editorial
Mazdutide: China's GLP-1/Glucagon Dual Agonist for Obesity
Mazdutide is the world's first approved GLP-1/glucagon dual agonist. GLORY-1 NEJM data, mechanism vs semaglutide, liver fat reduction, and global outlook.
Metabolic Science Editorial
GLP-1 and Pregnancy: Semaglutide, Tirzepatide and Planning
What current labels say about GLP-1 medicines before and during pregnancy, accidental exposure, contraception and why planning must be product-specific.
Metabolic Science Editorial
Bariatric Surgery vs GLP-1 Medications: Which Works Better?
Head-to-head data on bariatric surgery vs GLP-1 medications: weight loss percentages, diabetes remission, durability, and how to choose between them.
Metabolic Science Editorial
GLP-1 Medications and Sexual Function: What the Research Shows
GLP-1 drugs improve testosterone and erectile function in some men with obesity, but a FAERS signal and clinical reviews flag reduced libido. Here is what the 2025-2026 evidence actually shows.
Metabolic Science Editorial
GLP-1 Medications and Alzheimer's Disease: What the Research Shows
Phase 3 EVOKE trials of oral semaglutide failed to slow cognitive decline in early Alzheimer's, but biomarkers improved. Here is what the science actually shows.
Metabolic Science Editorial
GLP-1 and Gastroparesis: Stomach Slowing, Symptoms and Safety
How GLP-1-related stomach slowing differs from diagnosed gastroparesis, what Ozempic and Mounjaro labels say, and when symptoms need assessment.
Metabolic Science Editorial
GLP-1 Medications and Migraine: What the Research Shows
GLP-1 agonists may reduce migraine frequency and intracranial pressure. We review the exenatide IIH trial, weight loss data, and clinical implications.
Metabolic Science Editorial
GLP-1 Medications and Parkinson's Disease: What the Research Shows
A Phase 2 trial of lixisenatide slowed motor decline in early Parkinson's, but the largest Phase 3 study of exenatide found no benefit. Here's what the science says.
Metabolic Science Editorial
GLP-1 Medications for Adolescents: What the Research Shows
Wegovy and Saxenda are FDA-approved for adolescents 12 and older. Here's what STEP TEENS, AAP guidelines, and ongoing trials reveal about safety and efficacy in teens.
Metabolic Science Editorial
GLP-1 Medications for Heart Failure (HFpEF): What the Research Shows
Semaglutide and tirzepatide reduce hospitalizations, ease symptoms, and shrink left ventricular mass in obesity-related HFpEF. Here's what STEP-HFpEF and SUMMIT reveal.
Metabolic Science Editorial
GLP-1 Medications and Eye Health: NAION, Retinopathy, and Vision Risks
What 2024–2026 research, the WHO ACSoMP review, and the EMA label update show about Ozempic, Wegovy, and the rare optic-nerve risk known as NAION.
Metabolic Science Editorial
GLP-1 Medications and Pancreatitis: What the Research Shows
Acute pancreatitis is the safety question most patients ask about Ozempic and Wegovy. Here is what 60+ randomized trials, FDA data, and pharmacovigilance signals actually say in 2026.
Metabolic Science Editorial
GLP-1 and Gallbladder Disease: Risk, Evidence and Symptoms
What randomized trials show about GLP-1 gallbladder risk, how to interpret relative risk, and which abdominal symptoms need prompt medical assessment.
Metabolic Science Editorial
GLP-1 Before Surgery: Anesthesia, Fasting and Medication Plans
Should you stop Ozempic or Mounjaro before surgery? Understand risk-based guidance, liquid-diet precautions and what to confirm with the anesthesia team.
Metabolic Science Editorial
MariTide (Maridebart Cafraglutide): Amgen's Once-Monthly Obesity Drug
MariTide delivers up to 20% weight loss with monthly dosing. How Amgen's GLP-1 agonist + GIP antagonist works, phase 2 data, and what comes next.
Metabolic Science Editorial
GLP-1 Resistance: Why Ozempic Doesn't Work for 1 in 10 People
New 2026 research from Stanford and 23andMe identifies genetic variants that cause GLP-1 resistance — explaining why some patients see minimal weight loss on semaglutide and tirzepatide. Here's the science.
Metabolic Science Editorial
Survodutide: The Glucagon/GLP-1 Dual Agonist with 16.6% Weight Loss
Boehringer Ingelheim's survodutide hit its Phase 3 SYNCHRONIZE-1 endpoint with 16.6% sustained weight loss — and it does it through a mechanism no approved obesity drug shares. Here's the full evidence.
Metabolic Science Editorial
GLP-1 Medications and Menopause: What the Research Shows
Menopause redistributes fat to the abdomen and lowers metabolic rate. Here's what semaglutide and tirzepatide trials show for perimenopausal and postmenopausal women.
Metabolic Science Editorial
GLP-1 Weight Loss Plateau: Why It Happens and How to Break It
Weight loss on semaglutide and tirzepatide stalls around 12-18 months. Here's the science behind the GLP-1 plateau and evidence-based strategies to restart progress.
Metabolic Science Editorial
CagriSema: The First GLP-1 + Amylin Combo for Obesity
Phase 3 REDEFINE 1 data show CagriSema delivers 22.7% weight loss in non-diabetic adults — and an FDA decision is expected in 2026. Here's what the science actually says.
Metabolic Science Editorial
GLP-1 Medications and Cancer Risk: What the Research Shows
Recent studies of over 1.6 million patients suggest GLP-1 medications may reduce risk of 10 obesity-associated cancers — but a thyroid signal still demands attention. Here's the evidence.
Metabolic Science Editorial
GLP-1 Medications and Joint Pain: What the Research Shows
Discover how GLP-1 medications like semaglutide reduce joint pain in osteoarthritis and rheumatoid arthritis. Review of landmark clinical trials and mechanisms.
Metabolic Science Editorial
GLP-1 Medications and Type 2 Diabetes Remission
Can GLP-1 receptor agonists like semaglutide and tirzepatide induce type 2 diabetes remission? A review of the latest clinical evidence and what it means for patients.
Metabolic Science Editorial
Orforglipron: The Oral GLP-1 Pill for Weight Loss
Orforglipron is Eli Lilly's oral small-molecule GLP-1 receptor agonist. Phase 3 trials show up to 11.2% weight loss — no injections required. Here's what the science says.
Metabolic Science Editorial
Retatrutide: Triple-Agonist Drug with 24% Weight Loss
Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously, producing 24.2% weight loss in Phase 2 trials — beyond any current obesity drug.
Metabolic Science Editorial
Oral Semaglutide for Weight Loss: The New Wegovy Pill
The FDA-approved Wegovy pill delivers up to 16.6% weight loss in clinical trials. Learn how oral semaglutide works, how it compares to injections, and who it's right for.
Metabolic Science Editorial
GLP-1 Medications and Addiction: What the Research Shows
Emerging research reveals GLP-1 medications like semaglutide may reduce cravings for alcohol, opioids, and nicotine by targeting the brain's reward system. Here's what the science shows.
Metabolic Science Editorial
GLP-1 Medications and Insulin Resistance: What the Research Shows
How GLP-1 receptor agonists like semaglutide and tirzepatide reverse insulin resistance through hepatic, muscular, and adipose mechanisms — with clinical trial evidence.
Metabolic Science Editorial
GLP-1 Medications and Cholesterol: What the Research Shows
GLP-1 medications like semaglutide and tirzepatide improve cholesterol and triglycerides. Here's what clinical trials reveal about their lipid-lowering effects.
Metabolic Science Editorial
GLP-1 Medications and Fertility: What the Research Shows
Growing evidence links GLP-1 receptor agonists to improved fertility in women with PCOS and obesity. What 2024–2025 research reveals about safety, efficacy, and pregnancy planning.
Metabolic Science Editorial
GLP-1 Medications and Blood Pressure: What the Research Shows
How semaglutide and tirzepatide lower blood pressure through weight loss and direct vascular mechanisms — a review of the latest clinical trial evidence.
Metabolic Science Editorial
GLP-1 Medications and Thyroid Health: What the Research Shows
GLP-1 receptor agonists carry an FDA thyroid warning, but human evidence differs sharply from rodent data. Here's what clinical trials actually show about thyroid cancer risk and thyroid function.
Metabolic Science Editorial
GLP-1 Medications and Skin Health: What the Research Shows
GLP-1 receptor agonists like semaglutide may improve psoriasis and hidradenitis suppurativa, but also cause 'Ozempic face' and skin laxity. Here's what the evidence shows.
Metabolic Science Editorial
GLP-1 Medications and Inflammation: What the Research Shows
Beyond weight loss, GLP-1 medications like semaglutide reduce systemic inflammation through multiple pathways. Here's what clinical trials and mechanistic studies reveal.
Metabolic Science Editorial
GLP-1 Medications and Gut Health: What the Research Shows
How GLP-1 receptor agonists like semaglutide and tirzepatide affect gut microbiome diversity, intestinal barrier function, and inflammatory conditions — a review of the latest science.
Metabolic Science Editorial
GLP-1 Medications and Mental Health: What the Research Shows
Do GLP-1 medications like semaglutide affect depression, anxiety, and addiction? A review of the latest clinical research on psychiatric safety and brain health.
Metabolic Science Editorial
GLP-1 Medications and Hair Loss: What the Research Shows
Hair loss affects many GLP-1 users. Learn what the science says about why it happens, who is most at risk, and evidence-based strategies to minimize shedding.
Metabolic Science Editorial
GLP-1 Medications and Bone Health: What the Research Shows
GLP-1 medications may reduce bone mineral density during weight loss. Learn what clinical research reveals about fracture risk and how to protect your bones.
Metabolic Science Editorial
GLP-1 Medications and Brain Health: What the Research Shows
New research links semaglutide and other GLP-1 drugs to reduced dementia risk and neuroprotection. Here's what the science actually says about brain health.
Metabolic Science Editorial
GLP-1 Medications and Kidney Health: What the Research Shows
Learn how GLP-1 receptor agonists like semaglutide protect kidney function, reduce albuminuria, and slow CKD progression — backed by the landmark FLOW trial and 2024 meta-analyses.
Metabolic Science Editorial
GLP-1 for Fatty Liver and MASH: Wegovy Approval and Trials
Who Wegovy is approved for in MASH, what ESSENCE and tirzepatide trials measured, and why fatty liver, fibrosis and cirrhosis are different.
Metabolic Science Editorial
GLP-1 Medications for PCOS: What the Research Shows
GLP-1 receptor agonists like semaglutide and liraglutide show promising results for PCOS—improving insulin resistance, reducing androgens, and restoring menstrual cycles.
Metabolic Science Editorial
What Is Food Noise? How GLP-1 Medications Help Silence It
Food noise is the relentless mental chatter about food that drives overeating. Learn how GLP-1 medications like semaglutide reduce this cognitive burden scientifically.
Metabolic Science Editorial
GLP-1 Medications and Sleep Apnea: What the Research Shows
Tirzepatide became the first FDA-approved drug for obstructive sleep apnea in 2024. Learn what clinical trials reveal about GLP-1 medications and OSA.
Metabolic Science Editorial
GLP-1 Medications and Alcohol: What the Research Shows
GLP-1 drugs like Ozempic may reduce alcohol cravings and intake. Explore the clinical evidence, neurobiological mechanisms, and practical safety guidance.
Metabolic Science Editorial
GLP-1 Medications and Muscle Loss: How to Preserve Lean Mass
GLP-1 drugs like semaglutide can cause lean mass loss alongside fat loss. Learn what clinical trials show and how resistance training and protein intake preserve muscle.
Metabolic Science Editorial
GLP-1 Medications and Heart Health: Cardiovascular Benefits Beyond Weight Loss
GLP-1 receptor agonists like semaglutide and liraglutide reduce major cardiovascular events, stroke, and heart failure risk—independent of weight loss alone. Here's what the evidence shows.
Metabolic Science Editorial
Tirzepatide vs Semaglutide: Which Is More Effective for Weight Loss?
A clinical comparison of tirzepatide (Zepbound/Mounjaro) and semaglutide (Wegovy/Ozempic) for weight loss, based on the SURMOUNT-5 trial and real-world evidence.
Metabolic Science Editorial
Weight Regain After Stopping GLP-1: What Trials Found
How much weight returned after semaglutide or tirzepatide withdrawal, what the STEP 1 and SURMOUNT-4 results mean, and questions for a follow-up plan.
Metabolic Science Editorial
Diet vs Medication for Weight Loss: What the Evidence Shows
A science-based comparison of dietary interventions vs GLP-1 medications for weight loss, including which approach works better and when to combine both.
Metabolic Science Editorial
Exercise with GLP-1 Medications: Preserving Muscle
Learn how to combine exercise with GLP-1 medications like semaglutide and tirzepatide to maximize fat loss, preserve lean muscle mass, and improve long-term outcomes.
Metabolic Science Editorial
Phentermine vs GLP-1 Medications: Which Is Right for You?
Compare phentermine and GLP-1 receptor agonists for weight loss. Evidence-based breakdown of efficacy, safety, cost, and how to choose between these two drug classes.
Metabolic Science Editorial
Bydureon vs Victoza: Which GLP-1 Is Right for You?
A science-backed comparison of Bydureon (exenatide ER) vs Victoza (liraglutide): HbA1c reduction, weight loss, cardiovascular outcomes, and side effects.
Metabolic Science Editorial
Trulicity vs Ozempic: A Clinical Comparison for 2026
Trulicity vs Ozempic: compare efficacy, weight loss, cardiovascular outcomes, side effects, and cost in this evidence-based clinical guide with 6 scientific citations.
Metabolic Science Editorial
How to Switch Between GLP-1 Medications Safely
A clinical guide to switching between GLP-1 receptor agonists — when to switch, how to transition, and what outcomes to expect based on current evidence.
Metabolic Science Editorial
Missed Dose Protocol for GLP-1 Medications: What to Do
Learn exactly what to do if you miss a dose of semaglutide, tirzepatide, or liraglutide — with evidence-based guidelines and pharmacokinetic data.
Metabolic Science Editorial
Traveling with GLP-1 Medications: The Complete Guide
How to travel safely with Ozempic, Wegovy, and Mounjaro — covering storage, TSA rules, injection schedules, and managing GI side effects on the road.
Metabolic Science Editorial
Rybelsus (Oral Semaglutide): Complete Guide to the Pill Form
Rybelsus is the first oral GLP-1 medication for type 2 diabetes and weight loss. Learn how it works, dosing, efficacy, side effects, and how it compares to injections.
Metabolic Science Editorial
Saxenda vs Wegovy: Which GLP-1 Wins for Weight Loss?
Head-to-head comparison of Saxenda (liraglutide 3mg) vs Wegovy (semaglutide 2.4mg) for weight loss, based on the STEP 8 trial and systematic reviews.
Metabolic Science Editorial
Ozempic Off-Label Use: What the Science Says
Discover the evidence behind Ozempic's off-label uses for cardiovascular disease, kidney disease, PCOS, liver disease, and alcohol use disorder.
Metabolic Science Editorial
Wegovy Dosing Schedule: Complete Step-by-Step Guide
The complete Wegovy (semaglutide 2.4mg) dosing schedule: from 0.25mg starter dose to maintenance, with clinical evidence on titration, side effects, and missed doses.
Metabolic Science Editorial
Semaglutide Dosage Guide: Titration, Maintenance & Adjustments
Complete semaglutide dosage guide covering titration schedules for Wegovy, Ozempic, and Rybelsus — with clinical evidence, dose adjustment tips, and missed dose protocols.
Metabolic Science Editorial
Tirzepatide vs Semaglutide: Head-to-Head Trial Evidence
Understand SURPASS-2 and SURMOUNT-5: populations, doses, average weight changes and the limits of calling one medicine better for everyone.
Metabolic Science Editorial
Tirzepatide: How It Works, Brands and Evidence
An introduction to tirzepatide, the difference between Mounjaro and Zepbound, what clinical comparisons show and questions to discuss with a prescriber.
Metabolic Science Editorial
Liraglutide (Saxenda & Victoza): Complete Guide
Everything you need to know about liraglutide — how it works, dosing, side effects, and how it compares to newer GLP-1 medications like semaglutide and tirzepatide.
Metabolic Science Editorial
GLP-1 Medication Side Effects: What You Need to Know
Comprehensive guide to GLP-1 medication side effects including semaglutide, tirzepatide, and liraglutide. Learn about common, rare, and serious adverse effects.
Metabolic Science Editorial
Ozempic vs Wegovy: What's the Difference?
Compare Ozempic and Wegovy—two semaglutide medications. Learn about dosages, approved uses, insurance coverage, and which might be right for you.
Metabolic Science Editorial
What is Semaglutide? A Complete Guide to This Revolutionary Weight Loss Medication
Learn everything about semaglutide, how it works for weight loss, its effectiveness, side effects, and what to expect when starting treatment.
Metabolic Science Editorial